Adnan Tufail MD, FROphth

Adnan’s professional life has been devoted to the treatment of blinding disorders of the retina. His research has led to a better understanding of the causes and treatments of the most common of these disorders – age-related macular degeneration and diabetic retinopathy. Surgically he specializes in cataract surgery in patients with retinal disorders. He is the clinical and research lead at Moorfields Eye Hospital in London for age-related macular degeneration (AMD).

Since 2003, Adnan has been a Consultant Ophthalmologist at Moorfields Eye Hospital NHS Foundation Trust and was awarded the title of Professor at The Institute of Ophthalmology, UCL (University College London) in recognition of his contribution to eye research. Moorfields is one of the leading eye hospitals in the world and as a senior consultant in the medical retina department, he has critical experience in the diagnosis and management of rare retinal conditions and disorders on the complex interface between inflammatory eye disease (uveitis) and medical retina. Cataract surgery for people with retinal conditions is more complicated, particularly their pre-and post-operative care. Adnan is one of the leading surgeons in the UK with an interest in cataract surgery in patients with co-existing retinal disorders.

Adnan was the lead clinician scientist for clinical trials to treat choroidal neovascularisation, including the seminal ABC Trial that focused on examining bevacizumab for neovascular AMD and the REPAIR trial for myopia-related neovascularisation. Both studies had a profound effect on eyecare in the UK and internationally. His current research interests are wide-ranging from disease mechanisms and treatment discovery e.g. dry age-related macular degeneration, currently an untreatable condition, to using artificial intelligence systems to improve patient access to retinal care and creating safe data sharing so that physicians can pool their patient experience to improve eye care in the NHS. He is also Deputy Lead of the large 16 million euro multicentre European study of dry age-related macular degeneration MACUSTAR – you can find out more info here about this important research.